Stanazolol--an anabolic steroid that does not influence parathyroid hormone response to hypercalcemia in postmenopausal women
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8082059
DOI
10.1007/bf00334336
Knihovny.cz E-resources
- MeSH
- Anabolic Agents administration & dosage pharmacology therapeutic use MeSH
- Administration, Oral MeSH
- Time Factors MeSH
- Estrogens pharmacology MeSH
- Hypercalcemia blood metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Luteinizing Hormone blood metabolism MeSH
- Parathyroid Hormone blood metabolism MeSH
- Postmenopause blood physiology MeSH
- Osteoporosis, Postmenopausal blood metabolism MeSH
- Radioimmunoassay MeSH
- Stanozolol administration & dosage pharmacology therapeutic use MeSH
- Testosterone blood metabolism MeSH
- Calcium pharmacology MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anabolic Agents MeSH
- Estrogens MeSH
- Luteinizing Hormone MeSH
- Parathyroid Hormone MeSH
- Stanozolol MeSH
- Testosterone MeSH
- Calcium MeSH
Estrogen influences the calcium-induced suppressibility of parathyroid hormone (PTH) in postmenopausal women. We tested the hypothesis that parathyroid gland function is also sensitive to the anabolic steroid, stanazolol. The calcium-induced suppressibility of PTH was investigated in 11 osteoporotic postmenopausal women on two occasions, before and after 1 month's oral treatment with stanazolol. Compliance to treatment was checked by the determination of serum luteinizing hormone (LH) and testosterone. Serum intact PTH and ionized calcium were estimated before and 5, 60, and 120 minutes after I.V. calcium load. Calcium-induced PTH suppression was of a similar magnitude before and after stanazolol, although calcium increments were identical. The results imply that stanazolol--at biologically effective doses--does not affect PTH responsiveness to hypercalcemia in postmenopausal women.
